Cardiocomm Solutions Named 2017 Niche Healthcare / Telemedicine Technology Company of the Year by Acquisition Finance

Award recognizes consistent advances in ECG and multi-biosign monitoring technologies

Toronto, Ontario--(Newsfile Corp. - September 7, 2017) - Established medical electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. EKG ("CardioComm Solutions" or the "Company"), today announced it has received the ACQ5 award as the Niche Technology Company of the Year in the Healthcare and Telemedicine category. The ACQ5 2017 award is sponsored by Acquisition Finance which is published under license from the Metropolis International Group Ltd. The magazine is circulated to CEO's and CFO's as well as other corporate finance and private equity executives globally.

The 12th ACQ5 Global Awards focus on organisations that demonstrate an ability to deliver services and skills to meet clients' needs and who can adapt to changing market and regulatory conditions. The ACQ5 Global Awards winners are peer nominated and the award winner categories published in the Acquisition Finance magazine is circulated to 163,000 senior executives. The publication reviews the driving forces in various industries examines sector characteristics to provide information that supports M&A activity and foreign direct investment including information on investors, buyers and sellers.

CardioComm Solutions' award is based on demonstrated leadership, innovation and momentum in influencing the telemedicine and healthcare markets. The award recognizes CardioComm Solutions as a collaborator in clinical research, R&D projects with start-ups and academic groups as a facilitator in providing "software as a medical device" partnerships to help disruptive medical technologies see market readiness with reduced cycle times. The Company efforts in this regard have been confirmed by recent announcements of partnerships with companies active in the telemedicine markets and by other awards, such as the recently announced Best In Medical Software Development for 2017.

CardioComm Solutions plans to continue growing their recognition as a credible m-health and consumer wellness technologies provider and has implemented a strategy of expanding the licensed use of its well-developed ECG connectivity and management technologies as "back office" medical software to their partners and customers. Despite the diagnostic value of ECG monitoring, telemedicine platforms have not previously included ECG monitoring due to the existing complexity of device integration and associated regulatory controls. The Company believes 2018 will be a period when increasing regulatory and performance pressure will be placed on North American healthcare and telemedicine providers to develop better and updated healthcare platforms to support more comprehensive health monitoring capabilities. Specifically, CardioComm Solutions will benefit from the need of these providers to look to the use of credible and proven software controls and monitoring devices that can meet the performance and use expectations of a health authority approved medical device system. The ACQ5 Award also acknowledges that the Company pipeline of technologies will meet the unmet needs for enhanced data collection in telemedicine platforms. This is expected to push the boundaries for access to credible data, not just ECGs but other biosigns, for use in predictive analysis.

CardioComm Solutions will be providing further updates regarding their medical and consumer ECG recording technologies and award updates. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), the USA (FDA), China (CFDA) and Canada (Health Canada). To learn more about the CardioComm Solutions' products, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investor.relations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.